Could a common mineral slow Alzheimer's? new trial begins
NCT ID NCT07459959
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests whether lithium orotate, a form of the mineral lithium, is safe and reaches the brain in people with early Alzheimer's. Forty adults with confirmed Alzheimer's will take either the supplement or a placebo for 9 weeks. Researchers will measure lithium levels in spinal fluid and check for side effects, but this study is too small and short to tell if it helps memory or thinking.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lithium orotate
- What this could lead to
- If it works, this could point toward a new way to slow Alzheimer's by delivering lithium to the brain more safely.
- What could go wrong
- This is a very early, small trial focused on safety and brain levels, not on stopping the disease. It may show no benefit or cause side effects like kidney or thyroid issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your brain help unlock Alzheimer's secrets?
- Can a gene therapy clear the toxic tau tangle in Alzheimer's?
- Can a new drug tame Alzheimer's? early trial aims to find out
- A scan that sees Alzheimer's tangles? trial puts tau tracer to the test
- Can a pill clear the toxic proteins behind Alzheimer's?
- A light switch for better sleep? Alzheimer's trial tests wireless circadian lighting